EPS for Rexahn Pharmaceuticals, Inc. (RNN) Expected At $-0.13; Raven Industries (RAVN) Has 1.13 Sentiment

Raven Industries, Inc. (NASDAQ:RAVN) Logo

Raven Industries Inc (RAVN) investors sentiment decreased to 1.13 in 2018 Q3. It’s down -0.20, from 1.33 in 2018Q2. The ratio dived, as 76 investment managers increased and opened new equity positions, while 67 decreased and sold their stock positions in Raven Industries Inc. The investment managers in our database now have: 25.82 million shares, down from 25.88 million shares in 2018Q2. Also, the number of investment managers holding Raven Industries Inc in top ten equity positions was flat from 0 to 0 for the same number . Sold All: 11 Reduced: 56 Increased: 44 New Position: 32.

Analysts expect Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) to report $-0.13 EPS on March, 11.They anticipate $0.04 EPS change or 44.44% from last quarter’s $-0.09 EPS. After having $-0.15 EPS previously, Rexahn Pharmaceuticals, Inc.’s analysts see -13.33% EPS growth. The stock decreased 0.17% or $0.001 during the last trading session, reaching $0.579. About 619,014 shares traded. Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) has declined 47.57% since February 13, 2018 and is downtrending. It has underperformed by 47.57% the S&P500. Some Historical RNN News: 26/04/2018 – Rexahn to Present Clinical Data at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting; 12/03/2018 Rexahn Pharm: 2017 Net Loss $25.3M; 15/05/2018 – Rexahn Phase 2a Combination Study of RX-3117 and Abraxane in First-line Metastatic Pancreatic Cancer Patients Advances to Second Stage; 15/05/2018 – REXAHN PHARMACEUTICALS INC – SMC HAS CONFIRMED THAT COMBINATION OF RX-3117 AND ABRAXANE IS SAFE AND WELL TOLERATED; 22/04/2018 – DJ Rexahn Pharmaceuticals Inc, Inst Holders, 1Q 2018 (RNN); 15/05/2018 – Rexahn Pharm: Routine Safety Monitoring Committee Review Confirmed No Dose Reductions Necessary; 15/05/2018 – Rexahn Pharm: Two Drugs Can Be Given in Combination at Highest Recommended Doses for Both Agents; 07/05/2018 – REXAHN PHARMACEUTICALS INC – AS OF MAY 4, 2018, HAD $19.3 MLN IN CASH, CASH EQUIVALENTS AND INVESTMENTS; 12/03/2018 – Rexahn Pharm: 2017 Loss $0.92 Per Shr; 15/05/2018 – Rexahn Pharm: SMC Confirmed Combination of RX-3117 and Abraxane Is Safe and Well Tolerated

The stock increased 1.43% or $0.54 during the last trading session, reaching $38.35. About 41,616 shares traded. Raven Industries, Inc. (RAVN) has risen 9.75% since February 13, 2018 and is uptrending. It has outperformed by 9.75% the S&P500. Some Historical RAVN News: 23/03/2018 – Raven Industries, Inc. vs Capstan Ag Systems, Inc. | Terminated-Settled | 03/22/2018; 06/03/2018 – Raven Industries Targets 10 % Annualized Earnings Growth Over Long-term; 16/05/2018 – Raven Precision Agriculture Technology to Power Autonomous Solutions; 16/03/2018 – Raven Industries Closes Below 200-Day Moving Average; 17/05/2018 – Raven Industries 1Q EPS 61c; 06/03/2018 – RAVEN INDUSTRIES 4Q REV. $95.8M, EST. $93.3M; 06/03/2018 – Raven Industries 4Q EPS 23c; 17/05/2018 – RAVEN INDUSTRIES 1Q EPS 61C, EST. 49C (2 EST.); 22/05/2018 – Raven Industries Board Announces Cash Dividend of 13 Cents Payable on July 27, 2018; 01/05/2018 – Raven Industries Renames Subsidiary

More notable recent Raven Industries, Inc. (NASDAQ:RAVN) news were published by: Globenewswire.com which released: “Raven do Brasil Introduces Hawkeye Lite Nasdaq:RAVN – GlobeNewswire” on January 28, 2019, also Nasdaq.com with their article: “Validea’s Top Five Basic Materials Stocks Based On Motley Fool – 1/20/2019 – Nasdaq” published on January 20, 2019, Nasdaq.com published: “Raven Industries, Inc. (RAVN) Ex-Dividend Date Scheduled for January 10, 2019 – Nasdaq” on January 09, 2019. More interesting news about Raven Industries, Inc. (NASDAQ:RAVN) were released by: Nasdaq.com and their article: “Raven (RAVN) Gains From Innovation & Lower Taxes, Costs Rise – Nasdaq” published on December 03, 2018 as well as Globenewswire.com‘s news article titled: “Raven Industries Agrees to Acquire AgSync Nasdaq:RAVN – GlobeNewswire” with publication date: December 11, 2018.

Raven Industries, Inc., together with its subsidiaries, provides various products to clients in the industrial, agricultural, energy, construction, and aerospace/defense markets worldwide. The company has market cap of $1.38 billion. It operates in three divisions: Applied Technology, Engineered Films, and Aerostar. It has a 24.27 P/E ratio. The Applied Technology segment designs, makes, sells, and services precision agriculture products and information management tools that enable growers to enhance farm yields.

Diversified Investment Strategies Llc holds 3.17% of its portfolio in Raven Industries, Inc. for 77,135 shares. Garrison Financial Corp owns 82,109 shares or 1.86% of their US portfolio. Moreover, Profit Investment Management Llc has 1.73% invested in the company for 50,915 shares. The South Dakota-based First National Bank Sioux Falls has invested 1.57% in the stock. Vident Investment Advisory Llc, a Georgia-based fund reported 417,333 shares.

Since January 1, 0001, it had 2 insider purchases, and 0 insider sales for $35,432 activity.

Analysts await Raven Industries, Inc. (NASDAQ:RAVN) to report earnings on March, 5. They expect $0.34 earnings per share, up 41.67% or $0.10 from last year’s $0.24 per share. RAVN’s profit will be $12.22M for 28.20 P/E if the $0.34 EPS becomes a reality. After $0.36 actual earnings per share reported by Raven Industries, Inc. for the previous quarter, Wall Street now forecasts -5.56% negative EPS growth.

Raven Industries, Inc. (NASDAQ:RAVN) Institutional Positions Chart